BIOMAT Database Logo BIOMAT Database Logo

Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). 1992

T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
Department of Surgery II, Tokai University, Kanagawa, Japan.

A randomized, controlled trial of adjuvant immunochemotherapy with PSK (Kureha Chemical Industry Co., Tokyo, Japan) in curatively resected colorectal cancer was studied in 35 institutions in the Kanagawa prefecture. From March 1985 to February 1987, 462 patients were registered. Four hundred forty-eight of those patients (97.0 percent) satisfied the eligibility criteria. The control group received mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) administration for over six months. The PSK group received PSK orally for over three years, in addition to mitomycin C and 5-FU as in the control group. At the end of February 1990, the median follow-up time for this study was four years (range, three to five years). The disease-free survival curve and the survival curve of the PSK group were better than those of the control group, and differences between the two groups were statistically significant (disease-free survival, P = 0.013; survival, P = 0.013). These results indicate that adjuvant immunochemotherapy with PSK was beneficial for curatively resected colorectal cancer.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants

Related Publications

T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
August 2008, Cancer biotherapy & radiopharmaceuticals,
T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
[Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer. Cooperative Study Group of Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group].
February 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
[Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer--7-year survival--Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group].
September 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials.
April 2006, Cancer immunology, immunotherapy : CII,
T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
[Cooperative study of surgical adjuvant chemotherapy of colorectal carcinoma (second study): 3-year survival after surgery of non-curatively resected patients. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
October 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
June 1995, Japanese journal of clinical oncology,
T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
[Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer].
February 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
[Cooperative study of surgical adjuvant chemotherapy for colorectal cancer. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan].
September 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials.
January 2002, Journal of immunotherapy (Hagerstown, Md. : 1997),
T Mitomi, and S Tsuchiya, and N Iijima, and K Aso, and K Suzuki, and K Nishiyama, and T Amano, and T Takahashi, and N Murayama, and H Oka
[An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer].
August 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!